A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

Cited by (721)

Items 501–600 of 721

1. Use of Insulin Sensitizers in NASH
   Mouen A. Khashab, Naga Chalasani · 2007 · Endocrinology and Metabolism Clinics of North America
2. Cisapride decreasing orocecal transit time in patients with nonalcoholic steatohepatitis.
   Xiangsheng Fu, Feng Yan Jiang · 2006 · PubMed
3. Pathology of nonalcoholic fatty liver disease
   Ch. Kittas Tiniakos · 2007 · Annals of Gastroenterology
4. Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD)
   Alessandra Quercioli, Fabrizio Montecucco, François Mach · 2009 · Cardiovascular & Haematological Disorders - Drug Targets
5. Insulin resistance, inflammation, and nonalcoholic fatty liver disease in non-obese adults without metabolic syndrome components
   Seonah Kim, Jaekyung Choi, Mina K. Kim · 2012 · Hepatology International
6. Non-Alcoholic Fatty Liver Disease
   Hui‐Hui Tan, Jason Pik‐Eu Chang · 2010 · Proceedings of Singapore Healthcare
7. Insulin Resistance, Adipocyte Biology, and Thiazolidinediones: A Review
   Özlem Tarçın, Mandeep Bajaj, Sema Akalın · 2007 · Metabolic Syndrome and Related Disorders
8. NASH and thiazolidinediones: Not to be taken lightly
   Jean‐François Dufour · 2007 · Journal of Hepatology
9. Stéatose au cours de l’hépatite chronique C : rôle de l’insulino-résistance et des facteurs viraux
   Rami Moucari, Patrick Marcellin, Tarik Asselah · 2007 · Gastroentérologie Clinique et Biologique
10. Pathology of NAFLD
    Elizabeth M. Brunt, David Erwin Kleiner · 2013
11. Treatment of nonalcoholic steatohepatitis: Antioxidants or insulin sensitizers?
    Leon Anton Adams, Paul Angulo · 2004 · Clinical Gastroenterology and Hepatology
12. Benefits of Combining Sonchus brachyotus DC. Extracts and Synbiotics in Alleviating Non-Alcoholic Fatty Liver Disease
    Wen-wu Huang, Boyuan Shen, Xiumei Li, Tongcun Zhang, Xiang Qin Zhou · 2023 · Foods
13. Trans-ancestral rare variant association study with machine learning-based phenotyping for metabolic dysfunction-associated steatotic liver disease
    Robert K. Chen, Ben Omega Petrazzini, Áine Duffy, Ghislain Rocheleau, Daniel M. Jordan, Meena B. Bansal, Ron Do · 2025 · Genome biology
14. Recurrent nonviral liver disease following liver transplantation
    Ka‐Kit Li, James Neuberger · 2009 · Expert Review of Gastroenterology & Hepatology
15. Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice
    Hayder H. Al-Azzawi, Abhishek Mathur, Debao Lu · 2006 · Journal of Surgical Research
16. Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
    Lucia Carulli, Mauro Maurantonio, Lionel Hebbard, Enrica Baldelli, Paola Loria, Jacob George · 2012 · Current Pharmaceutical Design
17. Pathology of nonalcoholic steatohepatitis
    Yoon‐Mi Jeen, So‐Young Jin · 2009 · The Korean Journal of Hepatology
18. Efficacy of peroxisome proliferator activated receptor agonist in the treatment of virus-associated haemophagocytic syndrome in a rabbit model
    Wen‐Chuan Hsieh, Bau-Shin Lan, Yi‐Ling Chen · 2010 · Antiviral Therapy
19. Nonalcoholic Fatty Liver Disease
    M. Shadab Siddiqui, Arun Jayant Sanyal · 2015 · Wiley eBooks
20. Fatty Liver Disease
    DINA G. TINIAKOS, Quentin Mark Anstee, Elizabeth M. Brunt, Alastair D. Burt · 2023 · Elsevier eBooks
21. Associations of Insulin Resistance and High-Sensitivity C-Reactive Protein with Metabolic Abnormalities in Korean Patients with Type 2 Diabetes Mellitus: A Preliminary Study
    Yuchul Jeong, Beom Jun Lee, Wonjai Hur, Min Joon Lee, Se‐Hyeon Han · 2024 · Metabolites
22. Novel treatment strategies for patients with nonalcoholic fatty liver disease
    Brian P Lam, Zobair M. Younossi · 2011 · Clinical Investigation
23. Prevention Strategies for Hepatocellular Carcinoma
    Derek J. Erstad, Allen A Razavi, Li Shen, Kenneth K. Tanabe, Bryan C. Fuchs · 2019 · Molecular and translational medicine
24. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Choungwon Jung, Soyoung Park, Hyunah Kim · 2023 · PLoS ONE
25. Pioglitazone in the management of Type 2 diabetes and beyond
    Harald Sourij, Thomas C. Wascher · 2007 · Therapy
26. Structural Correlates of PPAR Agonist Rescue of Experimental Chronic Alcohol-Induced Steatohepatitis
    Teresa Ramirez, Ming Tong, Carol A. Ayala · 2012 · Journal of Clinical & Experimental Pathology
27. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
    Francesco Angelico, Cesare Alessandri, Maria Del Ben, Flavio Lirussi · 2013 · Cochrane Database of Systematic Reviews
28. Recent advances in the treatment of non-alcoholic fatty liver disease
    Flavia D. Mendes, Keith D. Lindor · 2005 · Expert Opinion on Investigational Drugs
29. La stéatohépatite non alcoolique
    Vlad Ratziu, Mohamed Tahiri, Luminita Bonyhay · 2005 · Annales d Endocrinologie
30. Non‐Alcoholic Fatty Liver Disease
    Mohamed H. Ahmed, Christopher D. Byrne · 2011 · Wiley eBooks
31. Nonalcoholic Fatty Liver Disease
    Curtis Kent Argo, Zachary H. Henry, Stephen Hugh Caldwell · 2017 · Wiley eBooks
32. Perfecting the Puzzle of Pathophysiology: Exploring Combination Therapy in the Treatment of Type 2 Diabetes
    Ridhi Gudoor, Austen Suits, Jay H. Shubrook · 2023 · Diabetology
33. Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease
    Pierre Bédossa, David Erwin Kleiner · 2015 · Springer eBooks
34. Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice
    Yuzuru Iizuka, Hyounju Kim, Satoshi Hirako, Kanako Chiba, Masahiro Wada, Akiyo Matsumoto · 2018 · Journal of Food and Drug Analysis
35. Intraperitoneal administration attenuates thiazolidinedione-induced hepatic steatosis in KKAy mice with increased hepatic peroxisome proliferator-activated receptor (PPAR)γ mRNA expression
    Junya Oribe, Tetsuya Kakuma, Miwa Haranaka, Kenjirou Okamoto, Masataka Seike, Hironobu Yoshimatsu · 2011 · Obesity Research & Clinical Practice
36. Nonalcoholic Fatty Liver Disease: Review
    Indrajit Kumar Datta, Anisur Rahman, Tareq Mahmud Bhuiyan, Md. Mohsin Kabir · 2012 · BIRDEM Medical Journal
37. Children's toxicology from bench to bed - Liver Injury (2): Mechanism of antioxidant therapy for nonalcoholic fatty liver disease
    Kimitaka Takitani, Hiroshi Miyazaki, Atsushi Yoden · 2009 · The Journal of Toxicological Sciences
38. Fast break on the fat brake
    Danielle B. Andrews, Jeffrey B. Schwimmer, Joel E. Lavine · 2008 · Hepatology
39. Immunohistochemical Analysis in Steatohepatitis
    Dale C. Snover · 2005 · American Journal of Clinical Pathology
40. Nonalcoholic Fatty Liver Disease
    Andrea Ewing Reid · 2010 · Elsevier eBooks
41. Metabolic correlation and management strategies of non-alcoholic fatty liver disease: An Asian Indian perspective
    Atul Luthra, Priyanka Nigam, Anoop Misra · 2007 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
42. Acanthosis Nigricans in Patients with Nonalcoholic Steatohepatitis: An Uncommon Finding
    Gabriel Ikponmosa Uwaifo, Mingliarti Tjahjana, Reneé J. Freedman · 2006 · Endocrine Practice
43. Esteatosis hepática no alcohólica. Puesta al día
    Llorenç Caballería, Pere Torán‐Monserrat, María Antonia Auladell Llorens, Guillem Pera · 2008 · Atención Primaria
44. Non-alcoholic fatty liver disease
    Rika Jamali, Arsia Jamali · 2010 · KAUMS Journal
45. Non-alcoholic steatohepatitis (NASH) - is it a part of the metabolic syndrome?
    János Fehér, Eszter Németh, Gabriella Lengyel · 2005
46. Nonalcoholic Fatty Liver Disease
    Stephen Hugh Caldwell, Curtis Kent Argo, Abdullah M. S. Al‐Osaimi · 2011 · Wiley eBooks
47. Stéatopathies métaboliques
    Maud Lemoine, Lawrence Serfaty · 2011 · La Presse Médicale
48. Immunohistochemical Analysis in Steatohepatitis Does It Have a Role in Diagnosis and Management?
    Dale C. Snover · 2005 · American Journal of Clinical Pathology
49. Clinical & Experimental Pathology
    Rongqin Ren, Yuri D. Fedoriw, Monte S. Willis · 2012
50. Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation
    Kinga Czarnecka, Paulina Czarnecka, Olga Tronina, Teresa Bączkowska, Magdalena Durlik · 2021 · Immunity Inflammation and Disease
51. Nonviral Hepatitis
    Kerry Wilbur · 2009 · Journal of Pharmacy Practice
52. Multifocal nodular nonalcoholic steatohepatitis: resolution with rosiglitazone.
    Charles H. Berkelhammer, Hugo Cuadros, Andrea Blumstein · 2007 · PubMed
53. Hépatopathie non alcoolique: de la stéatose à la cirrhose
    Isabelle Anne Leclercq, Christine L Sempoux · 2006 · Acta Endoscopica
54. Treatment of fibrosis in nonalcoholic fatty liver disease
    Maarouf A. Hoteit, Frank A. Anania · 2007 · Current Gastroenterology Reports
55. Current management of patients with nonalcoholic fatty liver disease
    Elzafir B. Elsheikh, Linda L Henry, Zobair M. Younossi · 2013 · Expert Review of Endocrinology & Metabolism
56. Les stéatopathies métaboliques : conséquences hépatiques du syndrome métabolique
    Rodolphe Anty, Philippe Gual, Pierre–Michel Huet, Yannick LE MARCHAND‐BRUSTEL, Albert Tran · 2007 · Gastroentérologie Clinique et Biologique
57. Different actions of peroxisome proliferator-activated receptors: molecular mechanisms and clinical importance
    G. Simonson, D. Kendall · 2006 · Current Opinion in Endocrinology & Diabetes
58. A Comparison of the Therapeutic Effects of Metformin, Pioglitazone and Vitamin E in Patients with Non-Alcoholic Fatty Liver
    Karone Shahebrahimi, Sh Zulnoorian, Afshin Almasi, Azam Sharifi, AA Keshvarz, Nazanin Farshchian · 2017 · DOAJ (DOAJ: Directory of Open Access Journals)
59. Economic value added--a framework for health care executive compensation.
    William O. Cleverley · 1993 · PubMed
60. Flavonoid–Sesquiterpenoid Hybrids from the Leaves of Syzygium simile and Their Anti-Lipid Droplet Accumulation Activities
    Ching-Ju Yang, Yu‐Chun Lin, Ho‐Cheng Wu, Chia‐Hung Yen, Chu‐Hung Lin, Yueh‐Hsiung Kuo, Hsun‐Shuo Chang · 2025 · Journal of Natural Products
61. Récepteurs nucléaires PPAR et hépatologie : implications physiopathologiques et thérapeutiques
    Sébastien Dharancy, Alexandre Louvet, Antoine Hollebecque, Pierre Desreumaux, Philippe Mathurin, Laurent Dubuquoy · 2008 · Gastroentérologie Clinique et Biologique
62. The obesity epidemic: The role of radiology
    Tom Joseph, David M. Naeger, Aliya Qayyum · 2011 · Applied Radiology
63. Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by 1H-Magnetic Resonance Spectroscopy
    Fan Ping, Xuan Wang, Jing Yang, Meicen Zhou, Wei Li, Lingling Xu, Yuxiu Li · 2016 · International Journal of Endocrinology
64. Nonalcoholic steatohepatitis (NASH): therapeutic approaches
    HP Buscher · 2004 · DMW - Deutsche Medizinische Wochenschrift
65. Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors
    Kyung-Hun Lee, Sang Hoon Park, Yu-Jin Kim, Kyung Rim Huh, Kwang Seon Min, Sun‐Young Jun, Kyoung Oh Kim, Cheol Hee Park, Taeho Hahn, Kyo-Sang Yoo et al. · 2010 · The Korean Journal of Hepatology
66. Nonalcoholic fatty liver disease: a review
    Fred F Poordad · 2005 · Expert Opinion on Emerging Drugs
67. The Actions of PPARγ Agonists on the Various Target Organs
    Jun Goo Kang, Cheol‐Young Park · 2011 · The Korean Journal of Obesity
68. Type 2 Diabetes and Developmental Origin of Non-Alcohol Fatty Liver Disease and Future Directions of Treatment
    Hassan I. El‐Sayyad, El Shahary · 2016 · Clinical and Experimental Pharmacology
69. NAFLD therapy and monitoring disease progression
    Pankaj Puri, Vijayalakshmi Aravindan Arun · 2017 · Tropical Gastroenterology
70. Therapieoptionen für die nicht-alkoholinduzierte Fettleber und Fettleberhepatitis
    Johannes Kluwe, Ansgar Wilhelm Lohse · 2005 · Der Internist
71. Nonalcoholic fatty liver disease: treatment
    Sang Hoon Park · 2010 · The Korean Journal of Internal Medicine
72. Association between non-alcoholic fatty liver disease and metabolic syndrome
    Rasheeta Sivapackianathan, Arthur J Asivatham, Mamun Al‐Mahtab, Tahseen Ahmad Chowdhury · 2010 · International Journal of Hepatology
73. Tratamiento de la enfermedad hepática por depósito de grasa
    Marta Cobo Martín, Pedro Luis Fernández-Gil, Javier Crespo · 2008 · Gastroenterología y Hepatología
74. Non-Alcoholic Fatty Liver Disease and Malignancy as Complications of Insulin Resistance
    Zachary T. Bloomgarden · 2005 · Metabolic Syndrome and Related Disorders
75. Hypertension and hepatic steatosis
    Matthew Brookes, Tariq H Iqbal, Brian T. Cooper · 2008 · Current Hypertension Reports
76. The interrelationship between insulin resistane and Alzheimer development
    Doaa Ahmad Ghareeb, Shimaa K. Mohamed, Mohamed El-Sayed · 2013 · Journal of Biomedical Science and Engineering
77. Interactions between non‐alcoholic fatty liver disease and hepatitis C viral infection
    Zobair M. Younossi · 2004 · Journal of Gastroenterology and Hepatology
78. The Insulin Resistance Syndrome: Concept and Therapeutic Approaches
    Gerald M. Reaven · 2007 · Springer eBooks
79. Carbohydrate, Fat and Protein Metabolism in Obesity
    José Eduardo Galgani, Vı́ctor Cortés, Fernando Carrasco N · 2015 · Springer eBooks
80. Late Complications of Liver Transplantation and Recurrence of Disease
    Michael Charlton, Krishna V Menon · 2005 · Elsevier eBooks
81. Beyond Subcutaneous Fat
    Richard L. Seip · 2012 · CRC Press eBooks
82. Predictors Related to the Non-alcoholic Fatty Liver Disease
    Ha-Young Na, Deok-Ju Baek, Sang‐Hyun Lee · 2010 · Korean Journal of Family Medicine
83. [Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis].
    Peter L. M. Jansen · 2005 · PubMed
84. Treatments for the Metabolic Syndrome
    M Hanefeld, Ulrike Schatz, Frank Schäper · 2011 · Wiley eBooks
85. Tratamiento médico de la hepatopatía grasa no alcohólica primaria
    Diego Moreno Sánchez · 2005 · Medicina Clínica
86. Non‐alcoholic fatty liver disease: more than ‘just a bit of fatty liver’
    Niru Goenka, S Subramanian, Philip J. Weston · 2007 · Practical Diabetes
87. A placebo-controlled trial of pioglitazone in patients with nonalcoholic steatohepatitis.
    Shahin Merat, Reza Malekzadeh · 2007 · PubMed
88. [Oral diabetes treatment. Which substance is indicated at which time?].
    Andreas Hamann, Michael Morcos, Peter P. Nawroth · 2004 · PubMed
89. Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients
    Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee et al. · 2025 · CPT Pharmacometrics & Systems Pharmacology
90. Non-alcoholic Fatty Liver Disease in Obesity
    Silvia Marinho Ferolla · 2015 · Springer eBooks
91. Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease
    Brittany Burns Dennis, Sandy Sallam, Brandon J. Perumpail, Neha D. Shah, Donghee Kim, George T. Cholankeril, Aijaz Ahmed · 2021 · Journal of Clinical Gastroenterology
92. Diabetes and Liver Disease
    Douglas Meyer, Henry Charles Bodenheimer · 2009 · Springer eBooks
93. Non-Alcoholic Fatty Liver Disease
    Elisabetta Bugianesi · 2009 · Frontiers of gastrointestinal research
94. Drug treatment and type 2 diabetes: the impact of liver disease
    MH Ahmed, Christopher D. Byrne · 2007 · Practical Diabetes
95. Insulin, other hypoglycemic drugs, and glucagon
    Renee C. Page · 2010 · Side effects of drugs annual
96. Obesity in potential living donors: Success with simplicity
    Michael Charlton · 2004 · Liver Transplantation
97. Esteatosis hepática y resistencia a la insulina: ¿qué ocurre primero?
    E. Esteve-Lafuente, Wifredo Ricart · 2006 · Clínica e Investigación en Arteriosclerosis
98. Insulin Resistance and PPARγ
    Bong Soo, Se Eun Park · 2006 · The Journal of Korean Diabetes Association
99. Pharmacologic Management of Non-Alcoholic Fatty Liver Disease
    George Boon‐Bee Goh · 2014 · Advances in Pharmacoepidemiology & Drug Safety
100. Improvement of liver function tests by antidiabetic agents: The need for multidirectional analysis
     Bruno L Vergès, J.-M. Petit, Benjamin Bouillet · 2015 · Diabetes & Metabolism